Business Context and Reporting Period
This Form 8-K Current Report was filed by Spruce Biosciences, Inc. on May 28, 2025. The Company, incorporated in Delaware, is an emerging growth company. Its common stock (Symbol: SPRB) began trading exclusively on the OTC Pink Marketplace on April 29, 2025. The filing primarily addresses the entry into a material definitive agreement regarding the issuance of preferred stock and the scheduling of the 2025 Annual Meeting of Stockholders.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial transaction disclosed is:
- Capital Raise: Issuance and sale of one share of newly designated Series A Preferred Stock to Michael Grey (Executive Chair) for a purchase price of $100.00.
- Liquidity/Debt: No information regarding debt levels, liquidity positions, or operating cash flows is provided in this report.
Material Changes
The filing details a material modification to the rights of security holders and corporate governance structure:
- Series A Preferred Stock Issuance: The Company issued one share of Series A Preferred Stock with 22,000,000 votes. This share is not convertible and has limited voting rights restricted solely to proposals regarding a Reverse Stock Split.
- Voting Mechanics Change: Previously, a Reverse Stock Split required approval by a majority of outstanding Common Stock. Now, it requires approval by a majority of the voting power of Common Stock and the Series A Preferred voting as a single class.
- Impact on Abstentions: The Series A Preferred votes in the same proportion as Common Stock votes actually cast (excluding abstentions). Consequently, abstentions and non-votes will have a minimal effect on the outcome of a Reverse Stock Split proposal, whereas they previously acted as votes against the proposal.
- Liquidation Preference: The Series A Preferred holder is entitled to receive $100.00 prior to any distribution to Common Stock holders in the event of liquidation.
Guidance, Outlook, and Corporate Events
2025 Annual Meeting of Stockholders:
- Date: Scheduled for July 22, 2025.
- Record Date: Close of business on May 30, 2025.
- Proposal Deadlines: Due to the meeting date being more than 30 days after the anniversary of the 2024 meeting, revised deadlines apply. Stockholder proposals under Rule 14a-8 must be received by June 5, 2025. Director nominations and other business proposals must also be received by June 5, 2025.
- Universal Proxy Notice: Stockholders soliciting proxies for director nominees other than the Company's nominees must provide notice by June 8, 2025.
Redemption of Series A Preferred: The share will be automatically redeemed for $100.00 immediately following stockholder approval of a Reverse Stock Split Proposal, or if ordered by the Board of Directors.
Investor Verification Checklist
- Verify the Company's current stock price and trading volume on the OTC Pink Marketplace following the April 29, 2025 transition.
- Review the full text of the Purchase Agreement (Exhibit 10.1) and Certificate of Designation (Exhibit 3.1) to understand all restrictions on the Series A Preferred Stock.
- Confirm the status of any pending Reverse Stock Split proposals and the specific ratio being considered.
- Monitor the Company's cash position and burn rate, as this filing indicates no new significant capital infusion beyond the $100 transaction.
- Check for the definitive proxy statement supplement regarding the time and location of the July 22, 2025 Annual Meeting.